Semaglutide vs Tirzepatide
Single versus dual incretin receptor engagement — the central comparison in current metabolic pharmacology.
Metabolic
Semaglutide
Long-acting GLP-1 receptor agonist studied extensively for incretin pathway signaling and glucose regulation in preclinical models.
Metabolic
Tirzepatide
Dual GIP and GLP-1 receptor agonist — a 39-amino-acid synthetic peptide studied for combined incretin pathway activity.
Side by side
| Dimension | Semaglutide | Tirzepatide |
|---|---|---|
| Molecular weight | 4113.58 g/mol | 4813.45 g/mol |
| Size class | long peptide | long peptide |
| CAS number | 910463-68-2 | 2023788-19-2 |
| Research area | metabolic | metabolic |
| Sequence | Not published as a linear sequence | Not published as a linear sequence |
| Available sizes | 5mg, 10mg, 20mg | 10mg, 20mg, 30mg |
| Entry price | $44 | $89 |
| Cost per mg | $6.45 | $6.63 |
Mechanism
Semaglutide
Semaglutide is a 31-amino-acid GLP-1 analog structurally modified at position 8 (Aib substitution) to resist DPP-4 degradation, with a C18 fatty diacid chain conjugated via a spacer at Lys26 that promotes albumin binding. These modifications extend its half-life substantially relative to native GLP-1, which has a circulating half-life measured in minutes. It is among the most heavily published peptides in modern metabolic research.
Tirzepatide
Tirzepatide is a synthetic 39-amino-acid peptide engineered from the native GIP sequence with structural modifications conferring agonism at both the GIP and GLP-1 receptors. A C20 fatty diacid moiety supports albumin binding and extended half-life. Its research interest lies substantially in the question of whether dual incretin agonism produces effects distinguishable from GLP-1 monoagonism.
Evidence quality
Mechanism is not the same as evidence. Where we have assessed the literature, the verdict is stated plainly.
Semaglutide
Evidence base: extensive, independently replicated, with published receptor-level and pharmacokinetic characterization.
Full research reference →Tirzepatide
Evidence base: strong receptor-level characterization and independent replication; GIP receptor directionality remains genuinely contested.
Full research reference →Research applications
Semaglutide
- Incretin receptor signaling and β-cell response studies
- Gastric emptying and satiety-pathway research in rodent models
- Comparative pharmacokinetics against dual and triple agonists
- Receptor binding affinity and selectivity assays
Tirzepatide
- Dual incretin receptor signaling and biased agonism studies
- Comparative studies against selective GLP-1 agonists
- cAMP accumulation and β-arrestin recruitment assays
- Adipose and hepatic metabolic pathway research
Common questions
What is the difference between Semaglutide and Tirzepatide?
Semaglutide is long-acting GLP-1 receptor agonist studied extensively for incretin pathway signaling and glucose regulation in preclinical models. Tirzepatide is dual GIP and GLP-1 receptor agonist — a 39-amino-acid synthetic peptide studied for combined incretin pathway activity. They differ in molecular weight (4113.58 vs 4813.45 g/mol) and in the pathways they are studied against.
Which is more cost-effective per milligram, Semaglutide or Tirzepatide?
Semaglutide is lower at approximately $6.45 per milligram at its best tier, against $6.63 for the other. Cost per milligram is only meaningful relative to the concentrations a given protocol requires, since these compounds are not used at comparable masses.
Can Semaglutide and Tirzepatide be studied together?
Combination designs appear in the published literature for a number of these compounds. Whether it is appropriate for a given protocol depends entirely on the model and endpoint. We supply research compounds and do not provide protocol guidance — consult the primary literature for your specific model.
How should Semaglutide and Tirzepatide be stored?
Store lyophilized powder at -20°C protected from light. Reconstituted solution is stable at 2-8°C for up to 30 days. For Tirzepatide: Store lyophilized powder at -20°C protected from light. Reconstituted solution stable at 2-8°C for up to 30 days.
Which has the stronger evidence base?
Semaglutide — Evidence base: extensive, independently replicated, with published receptor-level and pharmacokinetic characterization. Tirzepatide — Evidence base: strong receptor-level characterization and independent replication; GIP receptor directionality remains genuinely contested.
All products sold on this website are intended for research and identification purposes only. These products are not intended for human dosing, injection, or ingestion.
Comparison generated from Lyra Vital catalog data. Every specification is reconciled against the certificate of analysis for the shipped batch.